Search academic texts

Information × Registration Number 0212U000262, 0109U002163 , R & D reports Title To optimize pathogenetic therapy in children and teenagers with a chronic virus hepatites B directed on the prevention of risk of development cirrhosis of liver and improvement quality life of patients popup.stage_title Head Lukyanova E.M., Tzhypkun A.G., Registration Date 06-02-2012 Organization State organization "Institute of pediatrics, obstetrics and gynecology NAMS of Ukraine" popup.description2 At first was proved the difference of the main clinical manifestations of the disease, depending on the patient's age, level of viral load and infection routes. Involvement in the pathological process the kidneys, violation of the terms of sexual development, psycho-emotional state and improvement quality life of patients have been established, justified the expansion of diagnostic testing for HBV patient. It was established the diagnostic information content of indirect serological markers to identify fibrogenesis, of hepatocellular insufficiency by Childe Pie, changes in endothelial function regional circulation and to develop criteria for the risk of liver cirrhosis. The possibility of inhibition of fibrogenesis was established by inclusion in the basic treatment of patients with HBV donor of nitric oxide - the drug "Tivortin" and an inhibitor of fibrogenesis - the drug "Ursofalk", which is confirmed by the positive dynamics of clinical and paraclinical syndromes, improvement of endothelial function, improving quality of life of patients. Product Description popup.authors Багдасарова І.В. Гончаренко Н.І. Денисова М.Ф. Диба М.Б. Донской Б.В. Кудрей Ю.В. Манейчик Л.В. Музика Н.Н. Тарасюк Б.А. Чернега Н.В. Чернов А.В. popup.nrat_date 2020-04-02 Close